-

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nextdoor Holdings, Inc. (KIND) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (“Nextdoor” or the “Company”) (NYSE: KIND) investors concerning the Company’s possible violations of federal securities laws.

On March 1, 2022, Nextdoor released its fourth quarter and full year 2021 financial results, reporting an 18% decline in revenue growth and a 26% decline in average revenue per weekly active user (“ARPU”) growth. On this news, Nextdoor’s stock price fell $0.85, or 13.6%, to close at $5.39 per share on March 4, 2022, thereby injuring investors.

Then on November 8, 2022, Nextdoor disclosed that revenues during the third quarter of 2022 declined sequentially by $1 million and that the Company’s quarterly ARPU growth contracted by 12% compared to the prior year quarter. On this news, Nextdoor’s stock price fell approximately 11% to close at $2.06 per share on November 9, 2022, thereby injuring investors further.

If you purchased Nextdoor securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NYSE:KIND

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc....

Did You Lose Money on Everest Group, Ltd. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 11.4% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Everest Group, Ltd. ("Everest" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Everest Group, Ltd. (NYSE: EG) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 27, 2025 disclosure concerning Everest Group, Ltd.Investors with los...

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation comes after an October 22, 2026 disclosure concerning Merck & Co., Inc. Investors...
Back to Newsroom